Ki-67 quantification revealed a significant reduction in tumor cell proliferation by sunitinib treatment in HT-29PAR tumors by 30 ± 5% (81 ± 4% versus 56 ± 4% proliferating cells in PAR vehicle- versus sunitinib-treated mice; n = 4, P < 0.01; Figure 3C). Here, MKI67 is linked to neoplasm.